Development of EDTA Crosslinked Beta-Cyclodextrin for Use in Drug-Eluting Cardiovascular Stents
Primary Submission Contact
Dr. Jennifer Holt
Faculty Sponsor Email Address
Arts and Sciences
Drug-eluting stents (DES) reduce the occurrence of in-stent restenosis in patients who have a stent placed in cardiac arteries. However, current DES do not have a long enough window of drug release to prevent late in-stent restenosis. Beta-cyclodextrin (BCD), a polymer which is capable of drug elution, has a high biocompatibility, and is able to be refilled with drug, is polymerized using Ethylenediaminetetraacetic acid (EDTA). The EDTA-BCD polymer particles have shown good attachment on Cobalt Chromium cardiovascular stents through imaging with SEM and analysis with EDS. Drug release studies done on the particles have shown extended drug release, showing that EDTA-BCD polymers have the capability of being a refillable and biocompatible coating for cardiovascular stents that can reduce the occurrence of late in-stent restenosis.
Burkhart, Grace; Young, Kathleen; Mu, Nathan; and von Recum, Horst A., "Development of EDTA Crosslinked Beta-Cyclodextrin for Use in Drug-Eluting Cardiovascular Stents" (2019). Fall Interdisciplinary Research Symposium. 130.
Additional Presentation Information